Haleon (HLN) said Wednesday it is investing 65 million British pounds ($87.3 million) in a new oral health manufacturing facility in Shanghai in a bid to expand production of brands such as Sensodyne and Parodontax in China.
The company targets extending Parodontax distribution to 30 cities by the end of 2027, it said.
Haleon shares were down 1.1% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments